Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Behandeling van anale HSIL verlaagt risico anuscarcinoom
aug 2022 | HIV, Maag-darm-leveroncologie, Virale infecties